Technical Analysis for ACET - Adicet Bio, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 5.89 | 1.73% | 0.10 |
ACET closed up 1.73 percent on Friday, March 24, 2023, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New Downtrend | Bearish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | 1.73% | |
| Lower Bollinger Band Walk | Weakness | 1.73% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Possible NR7 | about 10 hours ago |
| Possible Inside Day | about 10 hours ago |
| Up 2% | about 12 hours ago |
| 60 Minute Opening Range Breakout | about 13 hours ago |
| Up 1% | about 13 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/13/2023
Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Disease Immune System Antibodies Cancer Immunotherapy Chimeric Antigen Receptor T Cell Therapies For Cancer Chimeric Antigen Receptor T Cell Immune Response Adoptive Cell Transfer Antigen
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Disease Immune System Antibodies Cancer Immunotherapy Chimeric Antigen Receptor T Cell Therapies For Cancer Chimeric Antigen Receptor T Cell Immune Response Adoptive Cell Transfer Antigen
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 21.87 |
| 52 Week Low | 5.64 |
| Average Volume | 536,126 |
| 200-Day Moving Average | 13.28 |
| 50-Day Moving Average | 8.01 |
| 20-Day Moving Average | 7.28 |
| 10-Day Moving Average | 6.92 |
| Average True Range | 0.54 |
| RSI | 30.56 |
| ADX | 25.72 |
| +DI | 11.32 |
| -DI | 34.45 |
| Chandelier Exit (Long, 3 ATRs) | 6.59 |
| Chandelier Exit (Short, 3 ATRs) | 7.27 |
| Upper Bollinger Bands | 8.68 |
| Lower Bollinger Band | 5.87 |
| Percent B (%b) | 0.01 |
| BandWidth | 38.67 |
| MACD Line | -0.57 |
| MACD Signal Line | -0.42 |
| MACD Histogram | -0.1535 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.28 | ||||
| Resistance 3 (R3) | 6.26 | 6.11 | 6.22 | ||
| Resistance 2 (R2) | 6.11 | 6.01 | 6.12 | 6.19 | |
| Resistance 1 (R1) | 6.00 | 5.95 | 6.06 | 6.02 | 6.17 |
| Pivot Point | 5.85 | 5.85 | 5.88 | 5.86 | 5.85 |
| Support 1 (S1) | 5.74 | 5.75 | 5.80 | 5.76 | 5.61 |
| Support 2 (S2) | 5.59 | 5.69 | 5.60 | 5.59 | |
| Support 3 (S3) | 5.48 | 5.59 | 5.57 | ||
| Support 4 (S4) | 5.50 |
